TriNav® INFUSION SYSTEM

Real-World Pressure-Enabled Drug Delivery™ (PEDD™) Study Shows Improved Clinical Outcomes and Meaningful Cost Avoidance When Comparing PEDD to Non-PEDD Patients

Demonstrating the benefit of PEDD in real-world practice for transarterial chemoembolization (TACE) and radioembolization (TARE).

Study

The largest real-world PEDD evidence study to date

Real-World Evidence (RWE) evaluates how medical interventions perform in actual clinical practice with real patients and workflows.

Robust methodology

Retrospective comparative effectiveness study using a database containing 300 million patient claims. Two-stage matching process to create a more rigorous study design: coarsened exact matching (CEM) followed by propensity score matching (PSM).

Population 1,206 Patients

- In 1:1 matched, two-stage analysis
- PEDD patients had significantly higher baseline disease burden, with higher Charlson Comorbidity Index scores (7.1 vs. 6.4)

603 PEDD Patients
(**515 TARE** Patients • **88 TACE** Patients)

603 Non-PEDD Patients

Clinical Outcomes

Better Tumor Targeting

+48% more drug delivered

- 13.9 vs. 9.4 units of doxorubicin delivered (TACE subgroup)

Reduced Overall Clinical Complications

21% less post-procedure fatigue

- 20.9% vs. 26.4% (TACE and TARE subgroup)

Patients With Higher Disease Burden Had Fewer Adverse Events

61% fewer 30-day inpatient admissions

- 8.0% vs. 20.5% (TACE subgroup)

Potentially Better For Preparing Patients for Combination Therapy

9x less lymphopenia

- 0.6% vs. 5.2% at high-adoption centers (TACE and TARE subgroup)
- For facilities that leverage PEDD more, institutional experience compounds the benefits.

Meaningful Cost Avoidance

$7,734
cost avoided per patient

- $3,135 from reduced 30-day post-procedure inpatient stays
- $4,599 from fewer post-procedure clinical complications

Post-procedure complications and readmissions may not be covered by payers.

Indications For Use TriNav Infusion Systems are intended for use in angiographic procedures. They deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.
Contraindications TriNav Infusion Systems are not intended for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).
Rx Only For the safe and proper use of TriNav Infusion Systems, refer to the individual Instructions for Use.

Gupta D, Liu Y, et al. Clinical outcomes of pressure-enabled drug delivery (PEDD) for trans-arterial chemoembolization and radioembolization. J Comp Eff Res. 2026.

Learn more at **trinavinfusion.com**